ijms-logo

Journal Browser

Journal Browser

New Insights in Antibody Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: 30 July 2025 | Viewed by 460

Special Issue Editor

Special Issue Information

Dear Colleagues,

Antibody therapy is extensively employed to treat several chronic diseases, from autoimmune diseases to cancer, as well as some infectious diseases.

While antibody therapy can be utilized to cure these diseases or at least mitigate inflammation or cytokine storms, adverse events can also occur. To enhance this therapy, humanized antibodies have been developed. However, the production of antibodies by the host remains a challenge, as these antibodies block these drugs. An example of this is the well-documented use of drugs that target tumor necrosis factor alpha (TNF-alpha), a factor involved in several chronic diseases such as psoriasis and inflammatory bowel disease (IBD). Researchers have therefore endeavored to reduce the immunogenicity of these antibodies when used as a drug in order to avoid their inactivation.

This Special Issue welcomes the submission of research or review articles that address the use of these drugs in several chronic, immune-mediated and infectious diseases. It also welcomes studies that aim to improve the half-life of these drugs without increasing the incidence of side effects.

Dr. Loredana Frasca
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biological therapy
  • antibody therapy
  • non-communicable diseases
  • infectious diseases
  • chronic disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

30 pages, 1033 KiB  
Review
Targeting Aging Hallmarks with Monoclonal Antibodies: A New Era in Cancer Immunotherapy and Geriatric Medicine
by Michele Dal Bo, Marta Gambirasi, Idris Vruzhaj, Erika Cecchin, Abbas Pishdadian, Giuseppe Toffoli and Amin Safa
Int. J. Mol. Sci. 2025, 26(11), 4982; https://doi.org/10.3390/ijms26114982 - 22 May 2025
Viewed by 296
Abstract
Aging is characterized by a progressive deterioration in physiological function and an increased susceptibility to age-related diseases, such as cancer. Monoclonal antibodies (mAbs) constitute a novel therapeutic approach aimed at addressing aging mechanisms such as cellular senescence, inflammaging, and immunosenescence. This text presents [...] Read more.
Aging is characterized by a progressive deterioration in physiological function and an increased susceptibility to age-related diseases, such as cancer. Monoclonal antibodies (mAbs) constitute a novel therapeutic approach aimed at addressing aging mechanisms such as cellular senescence, inflammaging, and immunosenescence. This text presents an overview of mAb methods aimed at the markers of aging and their potential application in cancer treatment. The mAbs can be categorized into senolytics, senescence-associated secretory phenotype (SASP) neutralizers, and immune checkpoint inhibitors, each targeting fewer aging-related pathways relevant to cancer therapeutic enhancement than the last. Translating promising preclinical evidence into enhanced efficacy and safety in cancer therapy presents challenges, particularly in older populations. This study examines the therapeutic efficacy of mAbs in the treatment of cancer and age-related disorders, focusing on their current and future roles in oncology practice. Full article
(This article belongs to the Special Issue New Insights in Antibody Therapy)
Show Figures

Figure 1

Back to TopTop